JP2017522352A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522352A5 JP2017522352A5 JP2017505440A JP2017505440A JP2017522352A5 JP 2017522352 A5 JP2017522352 A5 JP 2017522352A5 JP 2017505440 A JP2017505440 A JP 2017505440A JP 2017505440 A JP2017505440 A JP 2017505440A JP 2017522352 A5 JP2017522352 A5 JP 2017522352A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- group
- salt
- independently represent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 18
- 239000003112 inhibitor Substances 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 201000009267 bronchiectasis Diseases 0.000 claims description 6
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 5
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 4
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 4
- 206010069351 acute lung injury Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 3
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 102100029921 Dipeptidyl peptidase 1 Human genes 0.000 claims description 2
- 101710087078 Dipeptidyl peptidase 1 Proteins 0.000 claims description 2
- 206010014561 Emphysema Diseases 0.000 claims description 2
- 208000027004 Eosinophilic disease Diseases 0.000 claims description 2
- 208000004930 Fatty Liver Diseases 0.000 claims description 2
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 229940122236 Histamine receptor antagonist Drugs 0.000 claims description 2
- 101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 claims description 2
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 206010065390 Inflammatory pain Diseases 0.000 claims description 2
- 206010022489 Insulin Resistance Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 102100027998 Macrophage metalloelastase Human genes 0.000 claims description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims description 2
- 108050000258 Prostaglandin D receptors Proteins 0.000 claims description 2
- 102100024218 Prostaglandin D2 receptor 2 Human genes 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 208000002223 abdominal aortic aneurysm Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims description 2
- 230000001078 anti-cholinergic effect Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 229940121647 egfr inhibitor Drugs 0.000 claims description 2
- 208000010706 fatty liver disease Diseases 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 244000000010 microbial pathogen Species 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 230000003448 neutrophilic effect Effects 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 125000003566 oxetanyl group Chemical group 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims 1
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 claims 1
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 208000007474 aortic aneurysm Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000003073 chemokine receptor CCR9 antagonist Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14179458.6 | 2014-08-01 | ||
| EP14179458 | 2014-08-01 | ||
| PCT/EP2015/067271 WO2016016242A1 (en) | 2014-08-01 | 2015-07-28 | Substituted oxetanes and their use as inhibitors of cathepsin c |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017522352A JP2017522352A (ja) | 2017-08-10 |
| JP2017522352A5 true JP2017522352A5 (enExample) | 2018-09-06 |
| JP6529575B2 JP6529575B2 (ja) | 2019-06-12 |
Family
ID=51266130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017505440A Active JP6529575B2 (ja) | 2014-08-01 | 2015-07-28 | 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9440960B2 (enExample) |
| EP (1) | EP3174879B1 (enExample) |
| JP (1) | JP6529575B2 (enExample) |
| WO (1) | WO2016016242A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2699580T3 (enExample) | 2014-01-24 | 2018-02-24 | ||
| JP2021512904A (ja) * | 2018-02-07 | 2021-05-20 | インスメッド インコーポレイテッド | Ａｎｃａ関連血管炎の治療のためのある種の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニル］−１，４−オキサゼパン−２−カルボキサミド |
| SI3758708T1 (sl) | 2018-03-01 | 2025-04-30 | Astrazeneca Ab | Farmacevtski sestavki, ki vsebujejo (2S)-{(1S)-1-ciano-2-[4-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-5-il)fenil]etil}-1,4-oksazepan-2-karboksamid |
| AU2019306532A1 (en) | 2018-07-17 | 2021-03-04 | Insmed Incorporated | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis |
| CN116157687A (zh) | 2020-07-20 | 2023-05-23 | 英斯梅德股份有限公司 | 用于提取嗜中性粒细胞丝氨酸蛋白酶以及治疗二肽基肽酶1介导的病症的方法 |
| PL4129989T3 (pl) | 2020-08-26 | 2025-02-24 | Haisco Pharmaceuticals Pte. Ltd. | Pochodna nitrilu działająca jako inhibitor dipeptydylopeptydazy 1 i jej zastosowanie |
| WO2022053651A2 (en) | 2020-09-10 | 2022-03-17 | Precirix N.V. | Antibody fragment against fap |
| JP7693817B2 (ja) * | 2021-02-05 | 2025-06-17 | エス－インフィニティ ファーマシューティカルズ カンパニー リミテッド | １，４－オキサゼパンを含む縮合環誘導体 |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
| WO2024148308A1 (en) | 2023-01-06 | 2024-07-11 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
| TW202500548A (zh) * | 2023-06-27 | 2025-01-01 | 大陸商西藏海思科製藥有限公司 | Dpp1抑制劑中間體及其製備方法及在醫藥中的用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4125727A (en) | 1976-10-18 | 1978-11-14 | American Cyanamid Company | Method of preparing imidazoisoindolediones |
| US6960597B2 (en) | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
| JP4365094B2 (ja) | 2001-03-02 | 2009-11-18 | メルク フロスト カナダ リミテツド | カテプシンシステインプロテアーゼ阻害薬 |
| WO2004110988A1 (en) | 2003-06-18 | 2004-12-23 | Prozymex A/S | Protease inhibitors |
| TW200528440A (en) | 2003-10-31 | 2005-09-01 | Fujisawa Pharmaceutical Co | 2-cyanopyrrolidinecarboxamide compound |
| WO2006096807A1 (en) | 2005-03-08 | 2006-09-14 | Janssen Pharmaceutica N.V. | Aza-bridged-bicyclic amino acid derivatives as alpha 4 integrin antagonists |
| US7893093B2 (en) * | 2005-03-22 | 2011-02-22 | Virobay, Inc. | Sulfonyl containing compounds as cysteine protease inhibitors |
| JP5240201B2 (ja) | 2007-10-12 | 2013-07-17 | 富士通株式会社 | Ｉｐ電話自動試験システム及び方法 |
| WO2009074829A1 (en) | 2007-12-12 | 2009-06-18 | Astrazeneca Ab | Peptidyl nitriles and use thereof as dipeptidyl peptidase i inhibitors |
| WO2010128324A1 (en) | 2009-05-07 | 2010-11-11 | Astrazeneca Ab | Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750 |
| WO2010142985A1 (en) * | 2009-06-10 | 2010-12-16 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761 |
| US8524710B2 (en) * | 2010-11-05 | 2013-09-03 | Hoffmann-La Roche Inc. | Pyrrolidine derivatives |
| WO2012119941A1 (en) | 2011-03-04 | 2012-09-13 | Prozymex A/S | Peptidyl nitrilcompounds as peptidase inhibitors |
| US8999975B2 (en) | 2011-09-19 | 2015-04-07 | Boehringer Ingelheim International Gmbh | Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C |
| JP6218860B2 (ja) | 2013-03-14 | 2017-10-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤 |
| AU2015314355B2 (en) * | 2014-09-12 | 2019-06-20 | Boehringer Ingelheim International Gmbh | Spirocyclic inhibitors of Cathepsin C |
-
2015
- 2015-07-28 WO PCT/EP2015/067271 patent/WO2016016242A1/en not_active Ceased
- 2015-07-28 EP EP15739650.8A patent/EP3174879B1/en active Active
- 2015-07-28 JP JP2017505440A patent/JP6529575B2/ja active Active
- 2015-07-31 US US14/814,759 patent/US9440960B2/en active Active